EIF2AK3 and cancer: To enhance the therapeutic effect against various types of cancer and non-cancerous diseases, the use of several inhibitors with small molecules targeting ER sensors such as IRE1, PERK, and ATF6 (in combination with anticancer drugs in the case of cancer) has been investigated in preclinical and clinical studies [167,168].